KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with K i s of 97.4 nM and 43.5 nM for human and rat SGLT1 , respectively. The selectivity ratios ( K i for SGLT2/ K i for SGLT1 ) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > SGLT
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.